News|Articles|August 14, 2009

Uncovering the root cause of contamination and leveraging the collaborative learning loop of QbD -Aegis Whitepaper

External Link - article-619190.pdf

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!

Related Content

Nerve cell with blue background attacked by red antibodies - 3D illustration of autoimmune disease | Image Source: ©peterschreiber.media -stock.adobe.com

Repertoire Immune Medicines and Lilly Collaborate on Treatments for Autoimmune Diseases

BySusan Haigney

January 29th 2026

Rare diseases, medical concept surrounded by pills and medical supplies on gray background. Top view. | Image Credit: ©maicasaa -stock.adobe.com

Rare Disease Therapies: From Niche Experiment to Strategic Growth Engine

ByNathan Edwards, PhD

January 28th 2026

International day of Women and Girls in science is observed every year on February 11, The day recognizes the critical role women and girls play in science and technology. 3D Rendering | Image Credit: ©Waseem Ali Khan -stock.adobe.com

Innovations from Women in STEM

BySusan Haigney

January 28th 2026

Pulmonologist doctor, lungs specialist. Aesthetic handdrawn highlighted illustration of human lings. Dark grey background, studio photo and collage. | Image Credit: ©mi_viri -stock.adobe.com

GSK’s RSV Vaccine Approved in Europe

BySusan Haigney

January 27th 2026

Leveraging Next-Gen Therapies, Advanced Purification, and Strategic Collaborations in Pharma Production

BySusan Haigney,Zachary Zubulake

January 26th 2026

Uncovering the root cause of contamination and leveraging the collaborative learning loop of QbD -Aegis Whitepaper

Newsletter

Related Content

Repertoire Immune Medicines and Lilly Collaborate on Treatments for Autoimmune Diseases

Rare Disease Therapies: From Niche Experiment to Strategic Growth Engine

Innovations from Women in STEM

GSK’s RSV Vaccine Approved in Europe

Leveraging Next-Gen Therapies, Advanced Purification, and Strategic Collaborations in Pharma Production

Trending on Pharmaceutical Technology

US Government Shutdown: Treating Regulatory Lapses as Predictable Operational Risks

Repertoire Immune Medicines and Lilly Collaborate on Treatments for Autoimmune Diseases

Rare Disease Therapies: From Niche Experiment to Strategic Growth Engine

Cellares Secures $257M to Scale Global Cell Therapy Manufacturing

US Withdrawal From WHO Creates New Pharma Logistics Vulnerabilities